Evidence map›Paper›PMID 27047463›Full record

ArticleFrontiers in microbiology2016

Broad Spectrum Antimicrobial Activity of Forest-Derived Soil Actinomycete, Nocardia sp. PB-52.

Priyanka Sharma, Mohan C Kalita, Debajit Thakur

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Rhizobacterium streptomyces sp. NEAU-383 as a potential biocontrol agent to control tomato bacterial wilt.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  6. Article
  7. Antibacterial activity and biosynthetic potential of Streptomyces sp. PBR19, isolated from forest rhizosphere soil of Assam.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  8. Article
  9. Article
  10. Modeling of Effectiveness ofMolecules (Basel, Switzerland) · 2024
    Article
  11. Characterization of Actinobacteria strains in Lebanese soil with an emphasis on investigating their antibacterial activity.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  12. Optimizing the production and efficacy of antimicrobial bioactive compounds fromFrontiers in cellular and infection microbiology · 2024
    Article
  13. 3 Biotech · 2023
    Article
  14. Article
  15. Overview on Strategies and Assays for Antibiotic Discovery.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Priyanka SharmaMicrobial Biotechnology Laboratory, Life Sciences Division, Institute of Advanced Study in Science and Technology Guwahati, India.
Mohan C KalitaDepartment of Biotechnology, Gauhati University Guwahati, India.
Debajit ThakurMicrobial Biotechnology Laboratory, Life Sciences Division, Institute of Advanced Study in Science and Technology Guwahati, India.
Institute of Advanced Study in Science and Technology · INGauhati University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A mesophilic actinomycete strain designated as PB-52 was isolated from soil samples of Pobitora Wildlife Sanctuary of Assam, India. Based on phenotypic and molecular characteristics, the strain was identified as Nocardia sp. which shares 99.7% sequence similarity with Nocardia niigatensis IFM 0330 (NR_112195). The strain is a Gram-positive filamentous bacterium with rugose spore surface which exhibited a wide range of antimicrobial activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), Gram-negative bacteria, and yeasts. Optimization for the growth and antimicrobial activity of the strain PB-52 was carried out in batch culture under shaking condition. The optimum growth and antimicrobial potential of the strain were recorded in GLM medium at 28°C, initial pH 7.4 of the medium and incubation period of 8 days. Based on polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS) gene-targeted PCR amplification, the occurrence of both of these biosynthetic pathways was detected which might be involved in the production of antimicrobial compounds in PB-52. Extract of the fermented broth culture of PB-52 was prepared with organic solvent extraction method using ethyl acetate. The ethyl acetate extract of PB-52 (EA-PB-52) showed lowest minimum inhibitory concentration (MIC) against S. aureus MTCC 96 (0.975 μg/mL) whereas highest was recorded against Klebsiella pneumoniae ATCC 13883 (62.5 μg/mL). Scanning electron microscopy (SEM) revealed that treatment of the test microorganisms with EA-PB-52 destroyed the targeted cells with prominent loss of cell shape and integrity. In order to determine the constituents responsible for its antimicrobial activity, EA-PB-52 was subjected to chemical analysis using gas chromatography-mass spectrometry (GC-MS). GC-MS analysis showed the presence of twelve different chemical constituents in the extract, some of which are reported to possess diverse biological activity. These results confirmed that the presence of bioactive constituents in EA-PB-52 could be a promising source for the development of potent antimicrobial agents effective against wide range of microbial pathogens including MRSA.

Indexed as

antimicrobial activitybiosynthetic genesculturing conditionsGC-MSmicrobial pathogensNocardia sp.SEM

Identifiers

PMID27047463
PMCPMC4796592
OpenAlexW2334708274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.